Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 8/20 | 0.64 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | HTR2A | P28223 | 1/20 | 0.64 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.64 |
| ▸ | FBP1 | P09467 | 7/20 | 0.52 |
| ▸ | PPARG | P37231 | 5/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3900554 | 0.88 | PPARA (0.68) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL3341525 | 0.87 | PPARA (0.68) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL1550078 | 0.85 | PPARA (0.64) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL13763797 | 0.84 | PPARA (0.71) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL3286612 | 0.84 | PPARA (0.69) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL3484747 | 0.84 | PPARA (0.62) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL3483913 | 0.84 | PPARA (0.62) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL3484814 | 0.83 | PPARA (0.73) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL3291229 | 0.83 | PPARA (0.69) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL23582383 | 0.83 | PPARA (0.61) | PPARAABCB11CYP1A2CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2759540-A2 | Beta-3 receptor ligands and their use in therapy | Universita' Degli Studi di Bari (IT) | 2014-07-30 | — | — | EP | disclosed |
| US-8354412-B2 | Beta-3 receptor ligands and their use in therapy | UNIVERSITA' DEGLI STUDI DI BARI (IT) | 2013-01-15 | — | — | US | disclosed |
| US-20110288104-A1 | Beta-3 receptor ligands and their use in therapy | UNIVERSITA' DEGLI STUDI DI BARI (IT) | 2011-11-24 | — | — | US | disclosed |
| US-8017613-B2 | Beta-3 receptor ligands and their use in therapy | UNIVERSITA' DEGLI STUDI DI BARI (IT) | 2011-09-13 | — | — | US | disclosed |
| US-20100075977-A1 | BETA-3 RECEPTOR LIGANDS AND THEIR USE IN THERAPY | UNVERSITA' DEGLI STUDI DI BARI (IT) | 2010-03-25 | — | — | US | disclosed |
| US-20100004159-A1 | SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES | GENFIT (FR) | 2010-01-07 | — | — | US | disclosed |
| US-20100004159-A1 | SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES | GENFIT (FR) | 2010-01-07 | — | — | US | disclosed |
| US-20100004159-A1 | SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES | GENFIT (FR) | 2010-01-07 | — | — | US | disclosed |
| EP-2046722-A2 | BETA-3 RECEPTOR LIGANDS AND THEIR USE IN THERAPY | Universita' Degli Studi di Bari (IT) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008015558-A2 | BETA-3 RECEPTOR LIGANDS AND THEIR USE IN THERAPY | UNIVERSITA' DEGLI STUDI DI BARI (IT) | 2008-02-07 | — | — | WO | disclosed |
| WO-2008012470-A2 | SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATION AND USES | GENFIT (FR) | 2008-01-31 | — | — | WO | disclosed |
| US-6790865-B2 | 2-HYDROXY-2-(4-HYDROXYPHENYL)-1-METHYLETHYL)AMINO)ETHYL)PHENOXY OR IMINO)-2-METHYLPROPIONIC ACID DERIVATIVE EXCELLENT BETA 3-ADRENOCEPTOR STIMULANTS | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2004-09-14 | — | — | US | disclosed |
| EP-1072583-B1 | 2-METHYLPROPIONIC ACID DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | KISSEI PHARMACEUTICAL (JP) | 2004-09-01 | — | — | EP | disclosed |
| US-6696489-B1 | PHENOLIC AND PHENYLAMINO SUBSTITUENTS; BETA 3-ADRENOCEPTOR AGONISTS; OBESITY, HYPERGLYCEMIA, INTESTINAL HYPERMOTILITY, POLLAKIURIA, URINARY INCONTINENCE, DEPRESSION | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2004-02-24 | — | — | US | disclosed |
| US-20030166719-A1 | 2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl)amino)ethyl)phenoxy or imino)-2-methylpropionic acid derivative excellent beta 3-adrenoceptor stimulants | KISSEI PHARMACEUTICAL CO., LTD. | 2003-09-04 | — | — | US | disclosed |
| EP-1072583-A1 | 2-METHYLPROPIONIC ACID DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | Kissei Pharmaceutical Co., Ltd. (JP) | 2001-01-31 | — | — | EP | disclosed |
| US-5627205-A | ANTILIPEMIC AGENTS AND ANTIOXIDANTS | ADIR ET COMPAGNIE (FR) | 1997-05-06 | — | — | US | disclosed |
| US-5512595-A | FOR SUPPRESSION OF MEMBRANE LIPID PEROXIDATION, ANTILIPEMIC AGENTS | ADIR ET COMPAGNIE (FR) | 1996-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075977-A1 | BETA-3 RECEPTOR LIGANDS AND THEIR USE IN THERAPY | ADRB3, ADRB2, ADRB1 | PPARA 507/4885ABCB11 1891/4885CYP1A2 1985/4885 |
| US-20110288104-A1 | Beta-3 receptor ligands and their use in therapy | ADRB3, ADRB2, ADRB1 | PPARA 507/4885ABCB11 1891/4885CYP1A2 1985/4885 |
| US-20100004159-A1 | SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES | IPO5, PPIP5K2, IPO4 | PPARA 1045/4885ABCB11 402/4885CYP1A2 45/4885 |
| US-20030166719-A1 | 2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl)amino)ethyl)phenoxy or imino)-2-methylpropionic acid derivative excellent beta 3-adrenoceptor stimulants | ADRB1, ADRB2, ADRA2A | PPARA 323/4885ABCB11 512/4885CYP1A2 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.